Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

m its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release. PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statement of Operations(unaudited)Quarter Ended June 30, Year Ended June 30,2011201020112010REVENUESLicense and contract

$
24,691$
74,957$
497,540$ 14,180,727Grants

131,149-977,917-Total revenues

155,840674,9571,475,45714,180,727OPERATING EXPENSES:Research and development

3,217,3853,554,52110,377,01912,293,910General and administrative

1,525,0261,374,3204,751,8244,901,203Total operating expenses

4,742,4114,928,84115,128,84317,195,113Loss from operations

(4,586,571)(4,253,884)(13,653,386)(3,014,386)OTHER INCOME (EXPENSE):Investment income

26,91621,36599,258141,635Interest expense

(4,999)(3,862)(10,606)(13,165)Decrease/(increase) in fair value of warrants

1,255,425-(2,266)-Gain on sale of securities

--119,346-Gain/(loss) on disposition of supplies and equipment

--(5,666)95,000Total other income, net

1,277,34217,503200,066223,470Loss before income taxes

(3,309,229)(4,236,381)(13,453,320)(2,
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 ... by Product (1D & 2D Gel Electrophoresis, Agarose & ... MEKC, Reagents, Informatics), by Application & by End User ... Electrophoresis Market is expected to reach around $1.98 Billion ... forecast period 2015 to 2020. Browse ...
(Date:5/22/2015)... Charm Sciences, Inc. is pleased to ... Grain Inspection, Packers and Stockyards Administration (GIPSA) has ... to monitor aflatoxin in grains utilizing Charm’s ROSA ... Aflatoxin Quantitative Test (solvent-based). , The Charm ... Extraction Technology to extract aflatoxin from the sample ...
(Date:5/22/2015)... Knowledgent , the data and ... the potential of big data analytics in the life ... to help life sciences and healthcare organizations understand the ... critical business insights. , The life sciences and healthcare ... by patient profiling, compliance and regulatory requirements, and scientific ...
(Date:5/22/2015)... Baylor Research Institute (BRI) at ... Institute (TGen) in Phoenix, AZ , ... detection and treatments for patients with a broad range of ... to new clinical trials and access to technology to drive ... bench to bedside across Baylor Scott & White ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4
... Society of Forensic Toxicologists (SOFT) recognizes the recent ... Strengthening Forensic Science in the United States: A ... within the forensic sciences where improvements may be ... education, training, accreditation and certification in forensic science. ...
... superior to synthetic HRT with greater cardiovascular benefits ... 23 The most comprehensive analysis to date, ... peer-reviewed publication for practicing clinicians, showed that bioidentical ... are more efficacious than their synthetic counterparts. Conducted ...
... BOZEN, Italy, February 23 Health Robotics ... a definitive agreement whereby Can-Med,has acquired the ... in Armenia, Georgia, Kazakhstan, Uzbekistan, Azerbaijan,Iran, Mongolia, ... first and only automated, point-of-care-distributed, and fail-safe,robotic ...
Cached Biology Technology:The Society of Forensic Toxicologists Comments on the National Academy of Sciences' Report on 'Strengthening Forensic Science in the United States' 2New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 2New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 3Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3
(Date:5/21/2015)... , May 21, 2015 ... "Thermal Imaging Market by Solutions (Hardware, Software, Services), by ... Automotive & others), by End-Users (Military & Defense ... by MarketsandMarkets, Thermal Imaging Market is expected to ... Million by 2020, at a Compound Annual Growth ...
(Date:5/21/2015)... May 21, 2015 The Sync Project™ ... music for health, today announced a collaborative partnership with ... partnership will center on collaboration on original research, joint ... step in the collaboration, The Sync Project and BerkleeICE ... as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... 2010) The Association for Molecular Pathology (AMP) invites ... Annual Meeting and Exhibits and learn about the latest ... four-day event will feature more than 100 corporate exhibits, ... sessions. The keynote speaker is the distinguished recipient of ...
... Chemicals pervade our lives. While the benefits to society ... enabling safer, more efficient and more convenient consumer products ... side. Today, a growing awareness of the risks posed ... stimulated intensive investigations into their lifecycle and the unintended ...
... women who undergo in vitro fertilization (IVF) procedures suffer from ... therapy involved in IVF procedures is primarily responsible for this. ... this is true, other factors are even more influential. ... University,s Sackler Faculty of Medicine and the Sourasky Medical Center ...
Cached Biology News:New book examines health and environmental impacts of common (and not-so-common) chemicals 2New book examines health and environmental impacts of common (and not-so-common) chemicals 3Overcoming the IVF baby blues 2Overcoming the IVF baby blues 3
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Biology Products: